Private Label Tranexamic & Kojic Acid Body Wash Low MOQ

The minimum order quantity for a private label body wash containing both kojic acid and tranexamic acid depends heavily on whether you choose a stock formula, semi-custom, or fully custom development path. Stock or white-label formulas — where the manufacturer already has a brightening body wash base they can label with your brand — typically start at 200 to 500 units. Semi-custom routes, where a cosmetic chemist adjusts active percentages or fragrance to your spec, usually require 500 to 1,000 units to justify the reformulation cost. Fully bespoke development from a blank-sheet brief rarely drops below 1,000 units at any reputable contract manufacturer, and many won't consider it under 2,000 to 3,000 units. The reason MOQ exists is batch economics: a mixing tank that holds 200 liters of product costs roughly the same to set up, clean, and certify as one that holds 2,000 liters. Smaller runs mean higher per-unit overhead for the manufacturer, and they price accordingly. Packaging is often the hidden MOQ constraint. Even if a manufacturer can fill 300 units of formula, the pump bottle supplier may require a minimum component order of 3,000 to 5,000 pieces for a custom-printed bottle. The workaround for small launches is to use the manufacturer's existing stock packaging — a generic white or amber pump bottle — with a custom label applied. This lets you launch at 200 to 500 units and upgrade to fully branded components at your second run once you have confirmed demand. Active ingredient cost is another variable. Pharmaceutical-grade kojic acid costs more per kilogram than cosmetic-grade, and some suppliers enforce their own minimum purchase quantities — sometimes 1 kg minimum, which represents a large percentage of actives needed for a 300-unit run. Manufacturers who already keep kojic acid in inventory pass that savings on to small-run clients. The most common mistake first-time founders make is underestimating packaging MOQ and then being forced to order 3,000 units of product just to match the 3,000-piece component minimum. Negotiating a stock-packaging launch first avoids this trap entirely. For large runs — 5,000 units and above — MOQ is rarely a constraint; the conversation shifts to lead time, quality control, and exclusivity of the formula. Some manufacturers will grant formula exclusivity (meaning they won't sell the same base to a competitor) only at 5,000 units or more per quarter. AJ Cosmo Labs lets you filter manufacturer listings by MOQ directly inside the app, so you can immediately see which partners can accommodate a 200-unit first run versus which require 2,000 units minimum — saving hours of cold-email research.

The cost to private label a tranexamic acid and kojic acid body wash has three main components: formula and manufacturing cost, packaging cost, and regulatory or testing cost. Understanding each bucket helps you build a realistic landed cost per unit before you set a retail price. Formula and manufacturing cost at low MOQ (200 to 500 units) typically runs $4 to $8 per unit for a stock formula and $8 to $18 per unit for a fully custom formula. The difference is amortized R&D: custom development fees — which range from $1,500 to $8,000 one-time depending on the manufacturer — are spread across the initial production run. On a 300-unit run, a $3,000 development fee adds $10 per unit before you've paid for a single gram of ingredients. On a 3,000-unit run, the same fee adds $1 per unit. Transexamic acid at 2 to 5% active load in a body wash adds roughly $0.50 to $2.00 per unit in ingredient cost depending on grade and sourcing. Kojic acid at 1 to 2% adds $0.30 to $1.00 per unit. These are estimates based on mid-2020s pharmaceutical-grade pricing; ingredient markets fluctuate, and your manufacturer's CoA-verified supplier may have different pricing tiers. Packaging cost for a 250 ml to 400 ml pump bottle in stock form runs $0.20 to $0.50 per unit. Custom-printed or custom-molded packaging at 3,000 to 5,000 piece minimums runs $0.60 to $2.00 per unit depending on material and decoration method (shrink sleeve, silkscreen, hot stamp). Labels on stock bottles are typically $0.05 to $0.20 per unit including printing. Testing and regulatory costs are often overlooked by first-time founders. A stability test (45°C accelerated, 3-month) costs $500 to $2,500 depending on the lab. A challenge test (preservative efficacy) runs $300 to $1,200. Safety assessment by a qualified EU-responsible person costs $800 to $2,500 if you plan to sell in Europe. US FDA cosmetic facility registration is free to submit but requires internal processes. A realistic total landed cost for a 500-unit semi-custom run, excluding marketing, is $8 to $14 per unit. A typical indie brand targets a 3x to 5x keystone markup, suggesting a retail price of $24 to $70 for a 250 ml bottle — which aligns with where brightening body washes sit in the market currently. The most common error is building a cost model without including development fees and testing costs, then being surprised when the manufacturer invoices for them separately. Ask every manufacturer for a full line-item quote that includes formula development, pilot batch, testing, filling, labeling, and packaging before you sign anything.

Development timelines for a custom kojic acid and tranexamic acid body wash depend on whether you start from a manufacturer's existing base or build from scratch, and how many revision rounds the formula requires. For a stock or semi-custom formula — where a cosmetic chemist adjusts an existing brightening base — the timeline from signed brief to finished prototype is typically 3 to 6 weeks. This stage includes active blending, pH adjustment, initial sensory evaluation, and basic compatibility checks. Fully custom formula development runs 6 to 12 weeks to a stable prototype. The cosmetic chemist must select and test a surfactant system compatible with both actives, optimize pH (4.5 to 5.5 for kojic stability), and incorporate an antioxidant package to prevent oxidation-driven discoloration. Each iteration takes 1 to 2 weeks if the lab has capacity. After a formula is approved, a pilot batch (10 to 50 liters) is produced to confirm scale-up behavior — surfactant foaming profiles, viscosity, and active distribution can all shift from bench to tank. Pilot batch production and review adds 2 to 4 weeks. Stability testing is the biggest timeline driver that founders underestimate. Accelerated stability at 45°C runs for a minimum of 12 weeks, and you typically want results before committing to a full production run. Real-time stability at ambient (25°C/60% RH) runs 12 to 24 months for a full shelf-life claim. Many brands launch with 3-month accelerated data and continue real-time testing in parallel — which is acceptable practice but comes with the risk of formula changes if long-term data reveals problems. Challenge testing (ISO 11930 preservative efficacy) takes 4 to 6 weeks at an independent microbiology lab. Adding it up: a semi-custom formula with existing stability data from the manufacturer can be ready for full production in 8 to 12 weeks. A fully custom formula with independent stability testing is realistically 18 to 26 weeks from brief to production-ready. The mistake first-time founders most commonly make is signing a retailer or e-commerce launch date before formula development starts, then being forced to rush stability testing — or worse, skipping it — which can result in product discoloration complaints from customers months after launch. Posting your brief through AJ Cosmo Labs connects you with manufacturers who have pre-existing brightening body wash bases, which is the fastest legal path to a shelf-ready SKU if speed-to-market is your priority.

Kojic acid is generally recognized as safe for cosmetic use in rinse-off products like body wash at concentrations of 1% to 2%, which is the range most commonly cited in published cosmetic dermatology literature and used by contract manufacturers worldwide. At these levels, the risk of skin sensitization is low, particularly in a rinse-off format where contact time is short (typically 30 to 120 seconds). In the United States, the FDA does not currently restrict kojic acid in cosmetics and has not placed it on any prohibited or restricted list. Brands must ensure their claims do not cross into drug territory — stating that a body wash "treats hyperpigmentation" or "acts like a prescription treatment" risks triggering FDA enforcement action. In the European Union, the situation requires more diligence. The Scientific Committee on Consumer Safety (SCCS) has reviewed kojic acid multiple times. An SCCS opinion concluded that kojic acid at 1% in face products is safe, with less definitive guidance for body products. The EU Cosmetics Regulation allows its use in leave-on and rinse-off products, but the SCCS noted that frequent whole-body application at higher concentrations warrants additional genotoxicity data review. Brands exporting to the EU should confirm the latest SCCS opinion and work with a qualified Responsible Person before launch. In Japan, kojic acid is actually approved as a quasi-drug active ingredient for skin-whitening at concentrations up to 2%, but the quasi-drug category requires regulatory approval rather than simple cosmetic notification. If you plan to export to Japan, consult a local regulatory specialist. In Canada, kojic acid is permitted in cosmetics. Health Canada's Cosmetic Ingredient Hotlist does not currently restrict it, but claims must remain cosmetic in nature. For body wash specifically — a rinse-off product — the European Food Safety Authority's skin penetration data suggests lower systemic exposure compared to leave-on products, which generally makes the safety argument easier to support. Still, any responsible contract manufacturer will require a product safety assessment signed by a qualified safety assessor before they fill a product for EU distribution. Contact dermatitis to kojic acid has been reported, primarily in occupational settings (bakers and sushi makers exposed to high concentrations over long periods). At 1 to 2% in a rinse-off body wash, the sensitization risk is considered low but not zero — which is why challenge testing and patch-test data are good practices to have in your product dossier. Always request a Certificate of Analysis confirming purity grade on each lot of kojic acid your manufacturer uses, as impurity profiles differ between food-grade and cosmetic/pharmaceutical-grade material.

Label claims on a tranexamic acid and kojic acid body wash must stay within the cosmetic definition in your target market — meaning they describe an effect on the appearance of skin, not a treatment or cure for a disease or condition. Getting this boundary right is one of the most important legal steps before launch. Permitted cosmetic claims in the United States (under FDA guidance) include language like: "visibly brightens skin," "evens skin tone over time," "reduces the appearance of dark spots," "improves radiance," "for a more luminous look," and "leaves skin looking more uniform." These claims are about appearance and perception, not mechanism. Claims that cross into drug territory — and that the FDA has historically flagged — include: "treats hyperpigmentation," "inhibits melanin production" (when framed as a drug mechanism), "lightens age spots" in a therapeutic context, "acts like hydroquinone," or anything suggesting the product alters skin function at a biological level in a lasting, structural way. The FDA's OTC drug monograph for skin-bleaching agents (which covered hydroquinone) is now effectively withdrawn, making the regulatory space somewhat fluid, but the cosmetic-vs-drug line remains. In the EU, claims must be substantiated with evidence and must not mislead consumers. The EU's Common Criteria for cosmetic claims (Regulation EC 655/2013) require that any claim be truthful, supported by adequate evidence, and not imply a medical effect. The phrase "skin-whitening" is used and permitted in EU markets but must be backed by efficacy data (typically in vitro or in vivo studies). For body wash specifically, claims must account for the rinse-off nature of the product. Claiming "deep pigmentation correction" on a wash-off product is difficult to substantiate because active contact time is short. A cosmetic chemist can recommend penetration enhancers (glycols, certain esters) to improve active delivery during limited contact time, and some manufacturers have supporting in vitro data for these systems. Transexamic acid is a relatively newer cosmetic active with less regulatory history than kojic acid. It is not FDA-classified as a drug in topical rinse-off use, and claims around "brightening" and "tone-evening" are broadly accepted. Some brands use the ingredient name directly in marketing — "formulated with tranexamic acid" — which is permissible and popular because consumer recognition of the ingredient is growing rapidly. Document your claim substantiation in a regulatory dossier before you launch. This includes in vitro or consumer-use study data, the safety assessment, and a legal review of every claim on your label and website. Retailers like Target and Ulta increasingly ask for this documentation during vendor onboarding.

Finding a credible private label cosmetic manufacturer for an actives-forward body wash — one that can demonstrate genuine formulation capability with brightening ingredients, not just toll-blending from your own supplied formula — requires more diligence than a basic Google search returns. Start by defining your non-negotiables: target MOQ, active ingredients (and acceptable concentration ranges), desired lead time, target markets (US-only vs. EU export), and certifications you need (ISO 22716 GMP, cruelty-free, vegan, organic). Manufacturers who lack ISO 22716 or equivalent GMP certification are a serious risk — FDA enforcement actions for cosmetic manufacturing violations overwhelmingly target non-GMP facilities. When evaluating a manufacturer, ask for: a list of reference formulas they have produced containing brightening actives; a sample Certificate of Analysis from a previous production run; their stability testing process and whether they conduct in-house or outsource to a third-party lab; their minimum formula development fee and whether it is refundable against production; and their fill-and-finish lead time once a formula is approved. Red flags include: inability to provide a CoA for actives they claim to use; development fees with no transparency on what's included; no dedicated cosmetic chemist on staff (relying entirely on supplier tech sheets); and refusal to provide a manufacturing agreement or NDA before requesting your full formula brief. Geography matters less than capability, but US-based manufacturers offer logistical simplicity for domestic launches and are generally easier to audit in person. Asian manufacturers — particularly in South Korea and China — often have deep expertise in brightening actives and competitive pricing, but add import logistics, longer shipping lead times, and require more rigorous document review. Trade directories, trade shows (Cosmoprof, NYSCC), and industry associations list manufacturers but don't vet them. The AJ Cosmo Labs iOS app was built specifically to address this gap — manufacturers in the marketplace have submitted capability profiles including active-ingredient experience, MOQ, lead times, and certifications, so you can filter and compare before reaching out. Posting a product brief through the app surfaces manufacturers who have explicitly listed brightening body wash as a capability, saving the weeks it typically takes to qualify leads manually. Always request samples of an existing brightening body wash formula before committing to development. A manufacturer who cannot send a comparable sample for evaluation — ideally with stability data attached — is not the right partner for an actives-focused SKU.

Tranexamic acid and kojic acid both address skin hyperpigmentation but work through completely different mechanisms, which is why combining them in a single formula can deliver broader brightening effects than either active alone. Kojic acid (5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one) is a naturally derived compound, typically produced by fermentation of Aspergillus oryzae. Its primary mechanism is chelation — it binds to the copper ions that tyrosinase (the enzyme responsible for melanin synthesis) requires as a cofactor. Without that copper, tyrosinase cannot convert tyrosine to DOPA and then to melanin. The result is reduced melanin production at the source. Kojic acid is one of the most well-studied and commercially mature brightening ingredients, with decades of use in cosmetics. Transexamic acid (trans-4-(aminomethyl)cyclohexanecarboxylic acid) was originally developed as an antifibrinolytic pharmaceutical used in surgery and to manage heavy bleeding. Its discovery as a brightening cosmetic active came from observations that patients receiving topical or oral tranexamic acid showed reduced melasma. Its cosmetic mechanism is distinct from kojic acid: it interrupts the keratinocyte-melanocyte signaling pathway, specifically blocking the release of arachidonic acid and prostaglandins that UV exposure triggers. Less melanin-stimulating signal reaches the melanocyte, so less melanin is produced in the first place. It also appears to reduce UV-induced plasminogen activator activity, which is associated with melasma. In practical terms, kojic acid acts directly on the melanin-producing enzyme, while tranexamic acid acts upstream on the cellular communication that tells the enzyme to activate. Combining them addresses the hyperpigmentation cascade at two points, which formulators find produces more noticeable and faster-visible results than either active alone — an argument that is both scientifically sound and commercially useful for marketing. For a rinse-off product like a body wash, both actives face a contact-time challenge: they need to reach viable skin layers in the roughly 30 to 120 seconds the product is on skin before rinsing. Tranexamic acid, being a smaller, water-soluble molecule, has reasonable penetration data in rinse-off formats. Kojic acid penetration in rinse-off is lower but supported by regular repeated use. Formulators sometimes add penetration enhancers — propylene glycol, niacinamide, or certain lipid esters — to support active delivery in short contact-time applications. From a formulation stability perspective, tranexamic acid is the easier active to work with: it is stable across a broad pH range (3 to 7) and does not discolor. Kojic acid is considerably more challenging — it oxidizes readily and can turn a formula pink, brown, or orange on exposure to light, heat, air, or alkaline pH. The formulator must keep pH at 4.5 to 5.5, use an antioxidant package, and recommend UV-protective packaging to maintain both efficacy and aesthetics across the product's shelf life.